Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study

BACKGROUND: Sodium‐glucose linked transporter 2 inhibition recently emerged as a promising therapy for reducing the risk of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). However, there is a lack of data endorsing its role in symptomatic HF patients. We sought to evaluate the s...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cardiol
Päätekijät: Núñez, Julio, Palau, Patricia, Domínguez, Eloy, Mollar, Anna, Núñez, Eduardo, Ramón, Jose María, Miñana, Gema, Santas, Enrique, Fácila, Lorenzo, Górriz, Jose Luis, Sanchis, Juan, Bayés‐Genís, Antoni
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Wiley Periodicals, Inc. 2018
Aiheet:
Clinical Investigations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6489772/
https://ncbi.nlm.nih.gov/pubmed/29663436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22899
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia